Description of the Immune Response to Yellow Fever Vaccination

NCT06718127 | Recruiting

• 1 other identifier: 2023-149
• Study Type: interventional
• Target: 38
• Locations: 1 country
• Sites: 1

Brief Summary

Vaccine protection depends on a specific adaptive immune memory. However, a little-explored aspect of certain live vaccines may provide beneficial, non-specific protection against infections or pathogens other than the one from which the vaccine is derived. This is the concept of innate immune memory or " trained immunity", which differs from adaptive memory in its non-specificity. Innate immune memory is triggered by exposure to immunostimulants, and offers protection against unrelated pathogenic threats for several months or even years. The project aims to carry out an exploratory study to observe, in the context of current practice, the immune response obtained after a subunit and a live attenuated vaccine

Conditions

Immunization; Infections

Keywords

immunology; Vaccine response

Outcome Measures

Primary Outcomes (1)

• Immunological profile of PBMCs, before and after yellow fever vaccination

  Cytokine production assays (e.g. TNFa, IL6, IL1b)

  6 months

Secondary Outcomes (1)

• Description of the response to TyphimVi® vaccine

  6 months

Study Arms (1)

People with an indication for primary immunization against yellow fever and typhoid

OTHER

People with an indication for primary immunization against yellow fever and typhoid and whose vaccination schedule includes two appointments 7 days apart

Biological: blood samples collection

Interventions

blood samples collection BIOLOGICAL

blood samples collected at D0 ,W1, W5, M3 and M6

People with an indication for primary immunization against yellow fever and typhoid

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age between 18 and 65
• Referred for immunisation against yellow fever and typhoid
• Any person with indication for the following vaccinations :
• Yellow fever
• Typhoïd
• Whose vaccination schedule includes two appointments 7 days apart
• Whose state of health is compatible with a single 51 ml blood sample collection
• Have consented to participate in the Ivory2 study
• Benefiting from a Social Security plan or equivalent

You may not qualify if:

• Anyone with a contraindication to yellow fever and/or typhoid vaccination.
• Any person who has been vaccinated against yellow fever and/or typhoid.
• Anyone who has lived in an endemic area (≥ 1 year) and/or has a history of Typhoid.
• Anyone who is unable to attend the visit 1-month after the typhoid vaccine injection.
• Women claiming to be pregnant or breast-feeding
• Anyone unable to give informed consent for participation

Sponsors & Collaborators

• Institut Pasteur: lead

Study Sites (1)

Centre Médical de l'Institut Pasteur

Paris, 75015, France

RECRUITING

MeSH Terms

Conditions

Infections

Study Officials

• Fabien Taieb, Dr

  Institut Pasteur

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jessica Quintin, Dr

CONTACT

144389454; jessica.quintin@pasteur.fr

Sandrine Fernandes Pellerin

CONTACT

145688179; sandrine.fernandes-pellerin@pasteur.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 29, 2024
• First Posted: December 5, 2024
• Study Start: September 30, 2024
• Primary Completion: April 30, 2026
• Study Completion (Estimated): April 30, 2027
• Last Updated: June 29, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)